SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
WILMINGTON, Del., Feb. 05, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)?
- Did you purchase your shares between May 17, 2013 and December 28, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint (the “Complaint”) has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the common stock of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL) between May 17, 2013 and December 28, 2015, inclusive (the “Class Period”).
The Complaint alleges that the Company and certain of its officers and directors (“Defendants”) violated the Securities Exchange Act of 1934 by making materially false and misleading statements, and omitting material facts, about Anavex’s business, operations, and prospects.
According to the Complaint, Defendants misrepresented and/or failed to disclose that during the Class Period, the Company used a paid stock promoter to artificially inflate the price of Anavex stock. On December 29, 2015, the Company disclosed that it had been subpoenaed by the Securities and Exchange Commission in connection with “the recent unusual activity in the market for the Company’s shares.” On the day of that disclosure, the price of Anavex shares fell from a close of $7.03 per share to $6.29 per share. On the following day, December 30, 2015, Anavex’s stock price closed at $5.50 per share.
If you wish to serve as lead plaintiff, you must move the Court no later than February 29, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you suffered a loss in Anavex and would like to obtain additional information, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail at [email protected]; or at http://rigrodskylong.com/investigations/anavex-life-sciences-corp-avxl/.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
